Skip to main content


A better future

through education, skill development and research


Study Results May Lead to Improved Diagnostics for Breast Cancer

A study in Molecular Oncology indicates that examining the protein and RNA in leftover materials from routine diagnostic tests for breast cancer may lead to more accurate diagnoses.

Wednesday, July 18, 2018 12:01 am EDT

A study in Molecular Oncology indicates that examining the protein and RNA in leftover materials from routine diagnostic tests for breast cancer may lead to more accurate diagnoses.

Using samples from fine needle aspiration from 25 patients with breast cancer and 33 patients with benign lesions, investigators found that such a strategy could distinguish all cancer patient samples from all benign lesions.

In addition to providing a conclusive diagnosis, the analysis may prove valuable for subtyping of breast cancer, for determining appropriate therapies for individual patients, and for monitoring the course of disease and responses to therapy, all through minimally invasive techniques.

Additional Information

Link to Study:

About Journal

Molecular Oncology is an Open Access international journal that highlights new discoveries, approaches, as well as technical developments, in basic, clinical and discovery-driven translational cancer research.

The emphasis is on work that significantly advances our understanding of disease processes leading to human tumour development and/or establishes novel concepts of clear clinical significance in diagnosis, prognosis and prevention strategies for cancer patients.

Topics include, but are not limited to:

  • Key biological processes such as cell cycle; DNA repair; apoptosis; invasion and metastasis; angiogenesis and lymphangiogenesis; cell signalling and interactive networks; immune response.
  • Emerging technologies (genomics, proteomics, functional genomics, metabolomics, tissue arrays, imaging), and model systems.
  • Biomarkers: diagnosis, prognosis, stratification and efficacy.
  • Cancer genetics, epigenetics, and genomic instability.
  • Minimal residual disease, pre-malignant lesions.
  • Cancer micro-environment.
  • Molecular pathology.
  • Tumour immunology.
  • Translational research.
  • Cancer therapy (target discovery, drug design, immunotherapy, combination therapies, resistance, and individualised treatment).
  • Chemotherapy, radiotherapy and surgery.
  • Clinical pharmacology.
  • Clinical trials, integration of basic science into cancer clinical trials.
  • Molecular epidemiology.

About Wiley 

Wiley, a global research and learning company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 210 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at

Multimedia Files:

Preview image


Penny Smith (UK) +44 (0) 1243 770448
Follow us on Twitter @WileyNews

Business Wire NewsHQsm